Wang Yi

Director of the Institute of Rare Diseases, and an Outstanding Academic Leader in Shanghai. She is the Head of the Rare Disease Group of the Pediatrics Branch of the Chinese Medical Association, Standing Director of the Chinese Association Against Epilepsy, Vice Chairman of the Pediatric Neurology Committee of the Neurology Branch of the Chinese Medical Doctor Association, Vice Chairman of the Rare Disease Branch of the Chinese Hospital Association, Chairman of the Pediatrics Branch of the Shanghai Medical Association, President of the Shanghai Association Against Epilepsy, and Chairman of the Education Working Committee of the Chinese Association Against Epilepsy. Her research focuses on childhood neurodevelopmental disorders, with a particular emphasis on early diagnosis and prevention of childhood epilepsy, neuroprotective mechanisms and interventions, and systematic clinical epidemiological and translational research on autism spectrum disorders. She led the first domestic clinical IND study on novel gene therapy, conducted a Phase I/III clinical trial of VGN-R09b gene therapy for AADC deficiency, and established my country's first early screening cohort for childhood autism, increasing the early screening rate by nearly 30%. These findings were applied by the National Health Commission to formulate the "Guidelines for Screening and Intervention Services for Autism in Children Aged 0-6 (Trial)". Specializes in childhood epilepsy, drug-resistant epilepsy, various types of encephalitis, tic disorders, and rare and complex pediatric diseases. Has led 16 national and provincial-level research projects, published 211 academic papers, including over 100 SCI-indexed papers. Chief Scientist of the National Key Research and Development Program. Recipient of the "Good Doctor of China" award.